🇯🇵 Ch14.18 in Japan

PMDA authorised Ch14.18 on 23 June 2021

Marketing authorisation

PMDA — authorised 23 June 2021

  • Marketing authorisation holder: OHARA PHARMACEUTICAL Co.,Ltd.
  • Status: approved

Ch14.18 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in Japan

Frequently asked questions

Is Ch14.18 approved in Japan?

Yes. PMDA authorised it on 23 June 2021.

Who is the marketing authorisation holder for Ch14.18 in Japan?

OHARA PHARMACEUTICAL Co.,Ltd. holds the Japanese marketing authorisation.